← All trials
NCT04348656
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- Dec 31, 2020
- First posted
- Apr 16, 2020
- Last posted
- Apr 16, 2020
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hamilton Health Sciences CorporationLead sponsor
- McMaster UniversityOverall official - principal investigator
- University of TorontoCollaborator
- Canadian Blood ServicesCollaborator
- University of MontrealCollaborator
- New York Blood CenterCollaborator
- Héma-QuébecCollaborator
- Cornell UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.